Suppr超能文献

里瑟-埃尔斯沃思Vb组视网膜母细胞瘤患者初次外照射放疗后的结果

Outcome following initial external beam radiotherapy in patients with Reese-Ellsworth group Vb retinoblastoma.

作者信息

Abramson David H, Beaverson Katherine L, Chang Sidney T, Dunkel Ira J, McCormick Beryl

机构信息

Department of Ophthalmology, New York Presbyterian Hospital-Weill Medical College of Cornell University, 70 E. 66th Street, New York, NY 10021, USA.

出版信息

Arch Ophthalmol. 2004 Sep;122(9):1316-23. doi: 10.1001/archopht.122.9.1316.

Abstract

OBJECTIVE

To describe patient and ocular outcomes following initial treatment with external beam radiotherapy (EBT) in eyes with Reese-Ellsworth group Vb retinoblastoma.

METHODS

Retrospective case series (from January 1, 1979, to February 28, 2002). The Kaplan-Meier method was used to analyze survival (ocular and patient) and incidence (second cancer) data.

RESULTS

Two hundred forty-three patients with 1 or more Reese-Ellsworth group Vb eyes were identified. Of 284 group Vb eyes, 63 (22.2%) initially received EBT, vs 172 (60.6%) that were initially enucleated. Of the 63 radiated group Vb eyes, 31 (49.2%) had no further tumor growth, 26 (41.3%) developed a recurrence, and 8 (12.7%) developed a new tumor. Of the 63 radiated group Vb eyes, 33 (52.4%) developed ocular complications. The ocular survival rate of radiated group Vb eyes was 81.4% at 1 year and 53.4% at 10 years. Twenty-eight radiated group Vb eyes survived to the last follow-up with visual acuity information. Thirteen patients developed second cancers, 11 in the field of radiation. The probability of developing a second cancer following initial EBT for group Vb disease in patients with bilateral disease was 29.7% by 10 years after diagnosis. Survival from second cancers in patients with bilateral disease initially receiving EBT for group Vb disease was 93.6% at 5 years and 52.6% at 18(1/4) years. No patient with unilateral disease developed a second cancer. Deaths due to metastatic retinoblastoma were uncommon.

CONCLUSIONS

To our knowledge, this is the first study focusing exclusively on group Vb eyes treated initially with EBT, most of which were salvaged with vision. Outcome data provided herein are clinically relevant when choosing treatment options for advanced intraocular retinoblastoma.

摘要

目的

描述接受外照射放疗(EBT)初始治疗的Reese-Ellsworth Vb组视网膜母细胞瘤患儿的患者及眼部预后情况。

方法

回顾性病例系列研究(1979年1月1日至2002年2月28日)。采用Kaplan-Meier法分析生存情况(眼部及患者)和发病率(第二原发癌)数据。

结果

共确定243例患有1只或更多Reese-Ellsworth Vb组眼睛的患者。在284只Vb组眼睛中,63只(22.2%)最初接受了EBT,172只(60.6%)最初接受了眼球摘除术。在63只接受放疗的Vb组眼睛中,31只(49.2%)未出现肿瘤进一步生长,26只(41.3%)出现复发,8只(12.7%)出现新肿瘤。在63只接受放疗的Vb组眼睛中,33只(52.4%)出现眼部并发症。接受放疗的Vb组眼睛1年时的眼部生存率为81.4%,10年时为53.4%。28只接受放疗的Vb组眼睛存活至最后一次随访并提供了视力信息。13例患者发生了第二原发癌,其中11例发生在放疗区域。双侧患病患者最初接受Vb组疾病EBT治疗后10年发生第二原发癌的概率为29.7%。双侧患病患者最初接受Vb组疾病EBT治疗后,第二原发癌患者的5年生存率为93.6%,18(1/4)年生存率为52.6%。单侧患病患者未发生第二原发癌。因转移性视网膜母细胞瘤导致的死亡并不常见。

结论

据我们所知,这是第一项专门针对最初接受EBT治疗的Vb组眼睛的研究,其中大多数眼睛视力得以保留。本文提供的预后数据对于晚期眼内视网膜母细胞瘤治疗方案的选择具有临床参考价值。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验